Literature DB >> 14814204

Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.

S J FARBER, E Y BERGER, D P EARLE.   

Abstract

Entities:  

Keywords:  DIABETES MELLITUS; GLUCOSE

Mesh：

Substances：

Year:  1951        PMID： 14814204      PMCID： PMC436236          DOI： 10.1172/JCI102424

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  53 in total

1.  The effect of insulin on the excretion of glucose and phosphate by the kidney of the cat.

Authors:  M G EGGLETON; S SHUSTER
Journal:  J Physiol       Date:  1954-06-28       Impact factor: 5.182

2.  [The role of kidneys in carbohydrate metabolism].

Authors:  A KLEINSCHMIDT
Journal:  Klin Wochenschr       Date:  1953-10-01

Review 3.  Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A DeFronzo
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

Review 4.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

Review 5.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

Authors:  Ele Ferrannini; Anna Solini
Journal:  Nat Rev Endocrinol       Date:  2012-02-07       Impact factor: 43.330

6.  SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.

Authors:  Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

7.  Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition.

Authors:  Debapriya Basu; Lesley-Ann Huggins; Diego Scerbo; Joseph Obunike; Adam E Mullick; Paul L Rothenberg; Nicholas A Di Prospero; Robert H Eckel; Ira J Goldberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

Review 8.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors:  Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

9.  Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Authors:  Ele Ferrannini; Silvia Jimenez Ramos; Afshin Salsali; Weihua Tang; James F List
Journal:  Diabetes Care       Date:  2010-06-21       Impact factor: 19.112

10.  Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.

Authors:  James F List; Vincent Woo; Enrique Morales; Weihua Tang; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2008-12-29       Impact factor: 17.152
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.